ABOUT R&D PIPELINE INVESTORS & MEDIA CAREERS PRESENTATIONS & PUBLICATIONS ONCOLOGY PROGRAMS RETINAL / NGM621 ALDAFERMIN PRESENTATIONS ALDAFERMIN PUBLICATIONS NGM313 (MK-3655) OTHER PROGRAMS Initial results of a phase 1a/1b study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients with advanced solid tumors ESMO Virtual Congress; September 16-21, 2021 The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells Cancer Immunology Research, 2021 Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15 Nature, 2017 "I think it takes a certain energy to be here because there is a lot of energy here. You have to be willing to expend that energy and hustle and get things done and move at the pace that the company moves. It’s not for everyone, but I think that’s very exciting." MK Biology CAREER OPPORTUNITIES © 2021 NGM Biopharmaceuticals. All Rights Reserved. Contact. Privacy Policy. Terms of Use.

ABOUT R&D PIPELINE INVESTORS & MEDIA CAREERS CONTACT US Headquarters NGM Biopharmaceuticals, Inc. 333 Oyster Point Blvd. South San Francisco, CA 94080 phone: 650.243.5555 Inquiries: General information: info@ngmbio.com Business Development: bd@ngmbio.com Careers: careers@ngmbio.com Media: media@ngmbio.com © 2021 NGM Biopharmaceuticals. All Rights Reserved. Contact. Privacy Policy. Terms of Use.